4-((3S,5S,8R,9S,10R,13R,14S,17R)-3,5,14-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one

Catalog No. :
ACJAJF998
CAS No. :
514-39-6
Molecular Formula :
C23H34O5
Molecular Weight :
390.52

IUPAC Name:4-((3S,5S,8R,9S,10R,13R,14S,17R)-3,5,14-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one

4-((3S,5S,8R,9S,10R,13R,14S,17R)-3,5,14-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-((3S,5S,8R,9S,10R,13R,14S,17R)-3,5,14-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one
IUPAC Name4-((3S,5S,8R,9S,10R,13R,14S,17R)-3,5,14-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one
MDL No.-
Molecular FormulaC23H34O5
Molecular Weight390.52
SMILESC[C@]12CC[C@H](O)C[C@@]1(O)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@]12O
InChI KeyQJPCKAJTLHDNCS-FBAXFMHRSA-N
Synonym3-beta,5,14-Trihydroxy-5-beta-card-20(22)-enolide | Card-20(22)-enolide, 3,5,14-trihydroxy-, (3-beta,5-beta)- | Periplogenin | CCG-268535 | 3,5,14-Trihydroxycard-20(22)-enolide | s9168 | AKOS015897157 | CS-0022615 | UNII-B6808P7IY9 | HY-N2414 | (3.BETA.,5
CAS No.514-39-6
PubChem CID10574

Synthetic Route by SureRoute

1. ACJAJF998 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJAJF998 route product structure diagram
    ACJAJF998514-39-6
Inquiry

2. ACJAJF998 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJAJF998 route product structure diagram
    ACJAJF998514-39-6
Inquiry

Comments (0)